Collegium Pharmaceutical is a biotechnology company that focuses on developing innovative treatments for pain management and related conditions
The company specializes in formulating and bringing to market unique drug delivery systems and therapies that aim to enhance patient outcomes while addressing issues like opioid misuse and dependence. By leveraging advanced technology and scientific research, Collegium strives to provide healthcare professionals and patients with effective and safer alternatives for managing acute and chronic pain, contributing to improving overall quality of life.
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” has been selected as one of the top abstracts. This distinction includes recognition in AAPM’s Pain Medicine Journal, where the abstract will also be published.
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX) and the rest of the branded pharmaceuticals stocks fared in Q4.
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025.
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025.
STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:
– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million –
STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024.
